1. Generics Bulletin
  2. >>Products

Cipla Targets Global Respiratory Biosimilars With Kemwell JV

Indian Firm Will Bring Its ‘Respiratory Prowess’ To Planned Venture

 
• By Dean Rudge

Cipla is to establish a new company with CDMO Kemwell Biopharma to develop and launch biosimilars for the global market, especially in the respiratory space, where Cipla has built a considerable presence for inhalation products.

Start Launch
Cipla is to hold a 60% stake in the JV • Source: Alamy

Cipla Limited has announced plans to form a joint venture company with contract development and manufacturing organization Kemwell Biopharma to develop, manufacture and commercialize biosimilars for global markets, with an “aim to enter the respiratory biosimilars space.”

Under the terms of the agreement, the as yet unnamed joint venture will “leverage Cipla and Kemwell’s complementary strengths for end-to-end product development, clinical

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.